Nuance Pharma ("Nuance") announced that the Pharmaceutical Administration Bureau Macau approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) ...

Novel combination strategies are urgently needed to enhance efficiency of MWA. Conclusions: In this study, we found that the XIAP inhibitor AZD5582 modulates the immune microenvironment and inhibits ...

It is a first-in-class dual inhibitor of PDE3 and PDE4, targeting inflammation and bronchodilation in COPD patients. Moreover, Verona Pharma has partnered with Ritedose for the development and ...